{
  "source": "PA-Med-Nec-Daraprim.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2071-10\nProgram Prior Authorization/Medical Necessity\nMedication Daraprim® (pyrimethamine)\nP&T Approval Date 10/2015, 10/2016, 3/2018, 5/2019, 5/2020, 5/2021, 5/2022, 5/2023,\n5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nDaraprim® (pyrimethamine) is indicated for the treatment of toxoplasmosis when used conjointly\nwith a sulfonamide, since synergism exists with this combination.\nThe use of pyrimethamine for the treatment or prophylaxis of malaria is no longer recommended\nin the CDC Guidelines for the Treatment of Malaria in the United States. For the treatment of\nmalaria, contact the CDC Malaria Hotline: (770) 488-7788 or (855) 856-4713 toll-free Monday-\nFriday 9 am to 5 pm EST - (770) 488-7100 after hours, weekends and federal holidays.\nLimitations of Use:\nOutpatient medication access to Daraprim is available exclusively through the Daraprim Direct\nprogram in partnership with Optime Care, Inc.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Daraprim (pyrimethamine) will be approved based on submission of medical records (e.g.,\nchart notes) documenting one of the following criteria:\n1. Treatment of severe acquired toxoplasmosis, including toxoplasmic encephalitis\n-OR-\n2. Treatment of congenital toxoplasmosis\n-OR-\n3. Secondary prophylaxis of toxoplasmic encephalitis\n-OR-\n4. All of the following:\na. Primary Pneumocystis pneumonia (PCP) prophylaxis in HIV-infected patients or as\nsecondary prophylaxis in HIV-infected patients who have been treated for an acute\nepisode of Pneumocystis pneumonia\nb. Patient has experienced intolerance to prior prophylaxis with trimethoprim-\n© 2025 UnitedHealthcare Services, Inc.\n1\nsulfamethoxazole (TMP-SMX)\nc. One of the following:\n(1) Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX)\nusing a desensitization protocol and is still unable to tolerate\n(2) Evidence of moderately severe or life thr",
    "ollowing:\n(1) Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX)\nusing a desensitization protocol and is still unable to tolerate\n(2) Evidence of moderately severe or life threatening-reaction to trimethoprim-\nsulfamethoxazole (TMP-SMX) in the past (e.g., toxic epidermal necrolysis (TEN),\nStevens-Johnson syndrome)\n-OR-\n5. All of the following:\na. Primary prophylaxis of toxoplasmic encephalitis\nb. Toxoplasma IgG positive\nc. CD4 count ≤ 100 cells/mm3 if initiating prophylaxis or CD4 count < 100-200 cells/mm3\nif reinstituting prophylaxis\nd. Will be used in combination with dapsone or atovaquone\ne. Patient has experienced intolerance to prior prophylaxis with trimethoprim-\nsulfamethoxazole (TMP-SMX)\nf. One of the following:\n(1) Patient has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX)\nusing a desensitization protocol and is still unable to tolerate\n(2) Evidence of moderately severe or life threatening-reaction to trimethoprim-\nsulfamethoxazole (TMP-SMX) in the past (e.g., toxic epidermal necrolysis (TEN),\nStevens-Johnson syndrome)\nAuthorization will be issued for 12 months*\n* Consider discontinuation of primary prophylaxis if CD4 count > 200 cells/mm3 for > 3\nmonths after institution of combination antiretroviral therapy.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Daraprim [Package Insert]. Jersey City, NJ: Tilde Sciences LLC; October 2023.\n2. Centers for Disease Co",
    "ass.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Daraprim [Package Insert]. Jersey City, NJ: Tilde Sciences LLC; October 2023.\n2. Centers for Disease Control and Prevention. Treatment of Malaria (Guidelines For Clinicians).\nAccessed April 10, 2025: Clinical Guidance: Malaria Diagnosis & Treatment in the U.S.\n3. Centers for Disease Control and Prevention. CDC Yellow Book: Health Information for\nInternational Travel 2024. New York: Oxford University Press; 2024. Accessed April 10, 2025:\nhttps://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria\n4. Daraprim Accessing Daraprim. Accessed April 10, 2025:\nhttps://www.daraprimdirect.com/home/hcp#PO\n5. Department of Health and Human Services. Guidelines for the Prevention and Treatment of\nOpportunistic Infections in HIV-Infected Adults and Adolescents. Accessed April 10, 2025:\nGuidelines for the Prevention and Treatment of Opportunistic Infections in Adults and\nAdolescents With HIV\n6. Department of Health and Human Services. Guidelines for the Prevention and Treatment of\nOpportunistic Infections in HIV-Exposed and HIV-Infected Children. Accessed April 10, 2025:\nToxoplasmosis | Pediatric Opportunistic Infection | ClinicalInfo (hiv.gov)\nProgram Prior Authorization/Medical Necessity – Daraprim® (pyrimethamine)\nChange Control\n10/2015 New Program\n10/2016 Annual review. Updates to references.\n3/2018 Annual review. Updates to references, added criteria for PCP prophylaxis\nand clarified existing criteria.\n5/2019 Annual review. Updated background information without change to\ncoverage criteria. Updated references.\n5/2020 Annual review without change to coverage criteria. Updated references.\n5/2021 Annual review without change to coverage criteria. Updated references.\n5/2022 Annual review without change to coverage criteria. Updated references.\n5/2023 Annual review without change to clinical coverage criteria. Clarified\ndocumentation requirement. Updated references.\n5/2024 ",
    "nual review without change to coverage criteria. Updated references.\n5/2023 Annual review without change to clinical coverage criteria. Clarified\ndocumentation requirement. Updated references.\n5/2024 Annual review without change to coverage criteria. Updated references.\n5/2025 Annual review without change to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}